MBA 603 Bayer product assignment

.docx

School

Cleveland State University *

*We aren’t endorsed by this school

Course

603

Subject

Medicine

Date

Dec 6, 2023

Type

docx

Pages

3

Uploaded by MinisterMetalAnteater36

Assignment 5 - Breakthrough, Platform, Derivative Details 1. Breakthrough Product: Briviact (Brivaracetam) The anti-epileptic medication Briviact was created by UCB Pharma, which is now a Bayer subsidiary. It was given FDA approval in 2019 to treat adults with epilepsy who have partial- onset seizures (Mahmud & Mattson ,2019). Because it offers a new treatment option for patients who may not have responded to other medications, Briviact is a break-breaking product that represents a significant advance in the treatment of epilepsy. 2. Platform Product: Vyxeos (Moxetumomab Pasudotox-Tdfk) Vyxeos is a targeted cancer drug co-developed by Gilead Sciences and Bayer. It was approved by the FDA in 2020 for the treatment of acute myeloid leukemia (AML) in adults who have relapsed or are refractory to other treatments. According to Anselmo, & Mitragotri , 2019 Vyxeos acts as a platform product because it is based on the concept of targeted therapy, where it specifically targets the CD33 protein found on AML cells, delivering a toxic payload to the cancer cells while minimizing damage to healthy cells. 3. Derivative Product: Krystexxa (Pegloticase) Krystexxa is a biologic drug approved by the FDA in 2021 for the treatment of chronic gout in adults who have not responded to other treatments. Krystexxa can be considered a derivative product since it is based on the underlying biologic platform that allows it to break down uric acid crystals, providing relief for patients suffering from chronic gout (Ibrahim et.al.,2022).
2. How the acquisition of Monsanto by Bayer changed the resource allocation strategy? I think that the acquisition of Monsanto by Bayer had a significant impact on their resource allocation strategy. Combining Bayer's current skills with Monsanto's knowledge in agricultural biotechnology gave Bayer access to a wider variety of resources, which had an impact on how they approached research, development, and market expansion. By utilizing Monsanto's cutting- edge technology and biotech solutions, Bayer was able to devote more resources to agricultural research and development and concentrate on creating new and enhanced agricultural goods (Nacke, 2019). With the addition of Monsanto's product lines, which include seeds and herbicides, to Bayer's already-existing pharmaceutical and healthcare products, the company's resource allocation strategy was widened to include a more varied product portfolio, allowing it to serve a wider customer base and enter new market segments. The acquisition also facilitated Bayer's expansion into new geographic markets and regions where Monsanto had a strong presence, leading to resource allocation in optimizing the supply chain, distribution networks, and marketing strategies for enhanced global market penetration. Incorporating Monsanto's emphasis on sustainable agriculture practices, Bayer dedicated resources to developing eco-friendly products and technologies, addressing environmental concerns, and promoting responsible agricultural practices. Moreover, Bayer's resource allocation strategy was influenced by Monsanto's technological advancements, resulting in increased investments in cutting-edge technologies, precision farming, and digital tools, aimed at enhancing agricultural productivity and efficiency (Nacke, 2019). These strategic resource
Your preview ends here
Eager to read complete document? Join bartleby learn and gain access to the full version
  • Access to all documents
  • Unlimited textbook solutions
  • 24/7 expert homework help